Immunotherapy drug may keep High-Risk head and neck cancer at bay

NCT ID NCT02841748

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times

Summary

This study tests whether giving the immunotherapy drug pembrolizumab for one year after standard treatment can delay cancer recurrence in 100 people with high-risk head and neck cancer. Participants receive either pembrolizumab or a placebo, and researchers track how long they live without the cancer growing back. The goal is to see if this approach improves outcomes for patients at high risk of relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory University Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.